Myers

Business

Bristol Myers schizophrenia therapy safe in late-stage trial

hapabapa/iStock Editorial via Getty Images Bristol Myers Squibb (NYSE:BMY) announced Saturday that its experimental schizophrenia therapy KarXT, acquired as part…

Read More »
Back to top button